



## ORIGINALS

Bilingual edition English/Spanish

## Assessment of exposure-response relationship for cetuximab in patients with metastatic colorectal cancer and head and neck cancer

### Evaluación de la relación exposición-respuesta de cetuximab en pacientes con cáncer colorrectal metastásico y cáncer de cabeza y cuello

Silvia Peña-Cabía<sup>1</sup>, Ana Royuela-Vicente<sup>2</sup>, Ruth Ramos-Díaz<sup>3</sup>,  
Fernando Gutiérrez-Nicolás<sup>4</sup>, Benito García-Díaz<sup>1, 5</sup>, Ana López-Martín<sup>5,6</sup>

<sup>1</sup>Servicio de Farmacia, Hospital Universitario Severo Ochoa, Madrid, Spain. <sup>2</sup>Unidad de Bioestadística, Instituto de Investigación Sanitaria Puerta de Hierro- Segovia de Arana (IDIPHISA); CIBERESP, Madrid, Spain. <sup>3</sup>Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC); Hospital Universitario de Canarias (CHUC), Tenerife, Spain. <sup>4</sup>Unidad de Investigación, Hospital Universitario de Canarias (CHUC), Tenerife, Spain. <sup>5</sup>Universidad Alfonso X el Sabio, Madrid, Spain. <sup>6</sup>Servicio de Oncología Médica, Hospital Universitario Severo Ochoa, Madrid, Spain.

## Author of correspondence

Silvia Peña Cabía  
Avda. de Orellana, s/n  
28911 Leganés (Madrid), Spain.

Email:  
silviapcabia@gmail.com

Received 6 July 2021;  
Accepted 22 October 2021.  
Early Access date (11/29/2021).  
DOI: 10.7399/fh.11790

## How to cite this paper

Peña-Cabía S, Royuela-Vicente A, Ramos-Díaz R, Gutiérrez-Nicolás F, García-Díaz B, López-Martín A. Assessment of exposure-response relationship for cetuximab in patients with metastatic colorectal cancer and head and neck cancer. *Farm Hosp.* 2022;46(1):21-6.

## Abstract

**Objective:** There is limited scientific evidence on the cetuximab exposure-response relationship and no concentration threshold has been associated with optimal disease control. The aims were to assess, in a real-life setting, the relationship between steady state cetuximab concentrations ( $C_{\text{trough, SS}}$ ) and disease control.

**Method:** A prospective observational study in patients with metastatic colorectal cancer or head and neck cancer treated with cetuximab. Steady state trough concentrations were compared with the results of radiological assessment of response (progression or clinical benefit). Generalized estimating equations analysis was performed. To test the association between steady state concentrations and overall survival and progression-free survival, Cox proportional hazard models were developed. An optimal cut-off point was searched using the area under the receiver operating characteristic curve.

**Results:** A total of 30 steady state cetuximab concentrations from 16 patients were analysed. Median  $C_{\text{trough, SS}}$  was 26.86 mg/L and there was marked inter- and intraindividual variability (standard deviation).

## KEYWORDS

Cetuximab; Head and neck neoplasms; Colorectal neoplasms; Pharmacokinetics; Drug monitoring; Treatment outcome; Dose-response relationship.

## PALABRAS CLAVE

Cetuximab; Cáncer de cabeza y cuello; Cáncer colorrectal; Farmacocinética; Monitorización de fármacos; Resultados del tratamiento; Relación dosis-respuesta.

## Resumen

**Objetivo:** Evaluar, en condiciones de vida real, la relación entre las concentraciones valle en estado estacionario de cetuximab y el control de la enfermedad, así como buscar la relación entre estas concentraciones y la supervivencia. Además, estudiar si existe una concentración límite que se pueda asociar con la probabilidad de beneficio clínico.

**Método:** Estudio observacional prospectivo llevado a cabo en pacientes con cáncer colorrectal metastásico o cáncer de cabeza y cuello en tratamiento con cetuximab. Se realizó un análisis de regresión de ecuaciones de estimación generalizadas para evaluar la asociación entre la concentración valle en estado estacionario de cetuximab y la respuesta al tratamiento (progresión o beneficio clínico). Mediante modelos de riesgos proporcionales de Cox, se evaluó la asociación entre la mediana de concentraciones valle en estado estacionario de cetuximab en cada paciente o la última medida con la supervivencia global y la supervivencia libre de progresión, en cada una de las patologías. Asimismo, se buscó un punto de corte óptimo a través del área bajo la curva de características operativas del receptor.



Los artículos publicados en esta revista se distribuyen con la licencia  
Articles published in this journal are licensed with a  
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.  
<http://creativecommons.org/licenses/by-nc-sa/4.0/>  
La revista Farmacia no cobra tasas por el envío de trabajos,  
ni tampoco por la publicación de sus artículos.

tion 32.4 mg/L and 16.9 mg/L, respectively). A positive association was found between cetuximab  $C_{\text{trough, SS}}$  and clinical benefit (odds ratio 1.24, 95% confidence interval: 0.95-1.63,  $p = 0.113$ ), although without reaching statistical significance. The area under the receiver operating characteristic curve ( $n = 30$ ) had moderate discrimination power (0.71; 95% confidence interval 0.49-0.93), and the empirical optimal cutoff point was 19.12 mg/L. However, no association was observed between cetuximab  $C_{\text{trough, SS}}$  and survival in metastatic colorectal cancer or neck cancer patients.

**Conclusions:** We cannot confirm a relationship between cetuximab  $C_{\text{trough, SS}}$  and disease control despite a positive association. This study was conducted with a small sample, which reduces the power analysis. Further controlled randomised studies with a sufficient number of patients are needed.

## Introduction

Colorectal cancer (CRC) is the most common tumour in Spain (16%)<sup>1</sup>. It has a high mortality rate because 25% of patients have metastatic disease at the time of diagnosis and another 50% eventually develop metastases<sup>2</sup>. Head and neck cancer (HNC) accounts for 4% of all tumours.

Cetuximab is a chimeric IgG<sub>1</sub> monoclonal antibody (mAb) specifically targeting the extracellular domain of the epidermal growth factor receptor (EGFR)<sup>3</sup>. It has nonlinear pharmacokinetics<sup>4,6</sup> and is indicated for the treatment of patients with EGFR-expressing metastatic CRC (mCRC) with native RAS genes, and in patients with locally advanced, recurrent, and/or metastatic HNC<sup>3</sup>.

Dosing by body surface area or weight is a subject of debate regarding oncology drugs<sup>7</sup>, and mAb in particular<sup>8-10</sup>. Nevertheless, this strategy is widespread in clinical development, and is based on the theory that it reduces interindividual variability in drug distribution and elimination. However, mAb dosing based on body size tends to overdose larger patients and underdose smaller patients<sup>10</sup>.

On the other hand, mAbs fulfill the characteristics needed to perform pharmacokinetic monitoring and are designed to continuously neutralize their target antigens, which is achieved using minimal concentrations ( $C_{\text{trough}}$ )<sup>11</sup>. This aspect, coupled with their long elimination half-life, means that steady-state trough concentrations ( $C_{\text{trough, SS}}$ ) have the potential to adequately represent systemic exposure<sup>12</sup>. Thus, most mAb studies measuring exposure-response relationships have shown that  $C_{\text{trough}}$  is more relevant to predicting efficacy than either peak concentration ( $C_{\text{max}}$ ) or area under the curve<sup>13</sup>.

The main population pharmacokinetic studies conducted on oncology patients treated with cetuximab<sup>4,14-17</sup> have described its kinetic parameters, interindividual variability, and covariates. However, few publications have studied the relationship between cetuximab exposure and clinical response. Studies on patients with native KRAS mCRC have found a relationship between survival and clearance or  $C_{\text{trough}}$  at day 14<sup>4,18,19</sup>. Previous studies have also observed a relationship between overall clearance and survival<sup>15</sup> or between  $C_{\text{trough}}$  and clinical benefit<sup>6,20</sup> in patients with HNC.

As already performed with other mAbs<sup>21,26</sup>, the pharmacokinetic monitoring of cetuximab could serve as a tool to predict efficacy and, in the case of insufficient exposure, to adapt the patient's dosage. However, there is still little scientific evidence to support the therapeutic drug monitoring of mAbs used in oncological pathologies<sup>9,12,27</sup>.

The main objective of this study was to assess the relationship between the  $C_{\text{trough, SS}}$  of cetuximab and the clinical benefit rate. The secondary objectives were to investigate the relationship between  $C_{\text{trough, SS}}$  and survival and to study whether there is a threshold  $C_{\text{trough, SS}}$  that can be associated with the likelihood of clinical benefit.

## Methods

Prospective observational study conducted in a tertiary hospital. Inclusion criteria were as follows: adult patients on cetuximab treatment diag-

**Resultados:** Se analizaron 30 muestras de 16 pacientes. La concentración valle en estado estacionario mediana fue 26,86 mg/l y se encontró una gran variabilidad inter e intraindividual (desviación estándar de 32,4 y 16,9 mg/l, respectivamente). Se observó una asociación positiva entre la concentración valle en estado estacionario y el beneficio clínico (odds ratio 1,24; intervalo de confianza del 95%: 0,95-1,63;  $p = 0,113$ ), aunque no alcanzó significación estadística debido a la baja potencia. El área bajo la curva de características operativas del receptor de las concentraciones ( $n = 30$ ) tuvo una moderada capacidad discriminativa (área bajo la curva de características operativas del receptor 0,710; intervalo de confianza del 95%: 0,49-0,93) y el punto de corte estimado fue de 19,12 mg/l. Sin embargo, no se observó relación entre la supervivencia y las concentraciones valle en estado estacionario en ninguna de las patologías.

**Conclusiones:** No se ha podido confirmar una relación entre exposición a cetuximab y eficacia, a pesar de encontrar una tendencia positiva en el control de la enfermedad con el aumento de la concentración valle en estado estacionario. El nivel de evidencia se vio reducido por la pequeña muestra de pacientes en cada grupo, por lo que se necesitan estudios aleatorizados y controlados, con un número suficiente de pacientes, para evaluar adecuadamente esta relación.

nosed with mCRC or HNC, with measurable disease allowing assessment using RECIST criteria, and life expectancy more than 12 weeks. Exclusion criteria were as follows: poor venous access, any situation that prevented the patient from understanding their participation in the study, and patients who did not sign the informed consent form or were unable to sign it.

The samples were collected prospectively and then individual variables were collected retrospectively. The end of follow-up was January 31, 2020.

Cetuximab was administered according to standard clinical practice. Samples from each patient were obtained in  $C_{\text{trough, SS}}$  at the time of each assessment of treatment response, from inclusion in the study until the end of treatment, death, or study closure. The first scheduled extraction from any patient was after at least 12 weeks of mAb treatment because treatment response is not usually assessed at shorter intervals.

Blood samples were kept in 3-mL EDTA tubes, allowed to stand for 2 hours, and then centrifuged at 1,000 x g for 10 minutes. The plasma obtained was then stored at  $-20^{\circ}\text{C}$ .

Free cetuximab concentrations were determined using a validated Enzyme-linked Immunosorbent Assay (ELISA) technique: the SHIKARI Q-CET kit (Matriks Biotek Laboratories). We used the TRITURUS automated analyser (Grifols) and followed the manufacturer's specifications. Concentrations were expressed as mg/L. Each sample was analysed in duplicate and the mean was obtained as the result when the difference between the two values was less than 5%. For larger differences, the result was discarded and the analysis was repeated.

We recorded 55 individual variables (demographic, clinical, biochemical, treatment and response) in an Excel Data Collection Logbook. The information was compiled from the data recorded in the electronic assisted prescription software (Farhos, Visual Limes) and the hospital's clinical and administrative information system (Selene Hospitales, Cerner).

RECIST version 1.1 criteria were used to assess response every 12 weeks or when clinically indicated. The patients' tumour responses were classified into two categories: clinical benefit (stable disease [SD], partial response [PR], or complete response [CR]), or progression (PE).

Progression-free survival (PFS) was defined as the time elapsed between the first mAb administration and disease progression or all-cause mortality. Overall survival (OS) was defined as the time between the first mAb administration and all-cause mortality. Patients who did not experience either event were censored at the date of last contact.

To assess the association between cetuximab  $C_{\text{trough, SS}}$  and clinical benefit, we conducted a generalized estimating equations (GEE) regression analysis<sup>28</sup>. This analysis takes into account correlations between different  $C_{\text{trough, SS}}$  measurements over time for the same patient. The dependent variable was clinical benefit (yes/no) at each tumour assessment time point. The link function was *logit* and the covariance structure was exchangeable. The  $C_{\text{trough, SS}}$  of cetuximab at each time point was entered as the independent variable. The

odds ratio (OR) showed the association between each additional  $C_{\text{trough, SS}}$  of 10 mg/L cetuximab and clinical benefit. The corresponding 95% confidence intervals (95%CI) were also obtained.

Median follow-up was estimated using the inverse Kaplan-Meier method<sup>29</sup>. OS and PFS were assessed. Four univariate Cox proportional hazards models were constructed to assess the association between the median  $C_{\text{trough, SS}}$  of cetuximab (mg/L) or the last  $C_{\text{trough, SS}}$  measurement and each of the outcomes (OS and PFS in each pathology). Survival curves were estimated using the Kaplan-Meier method. Proportional hazard assumptions were assessed using Schoenfeld residuals.

An optimal cutoff point was estimated based on the Area Under the Curve of the Receiver Operator Characteristic (AUC-ROC).

A *P*-value of 0.05 was used as a cutoff for statistical significance. Analyses were conducted using Stata/IC v.16. software (StataCorp. 2019. *Stata Statistical Software: Release 16*. College Station, US).

The study was approved by the hospital Ethics Committee. Patients were recruited between February 2018 and January 2020. All patients gave signed informed consent.

## Results

A total of 16 patients on cetuximab treatment were included in the study. Two patients in the HNC group had a histological diagnosis of oesophageal cancer and were maintained in the response assessment, but were excluded from the survival analyses because of the possibility of having a different prognosis.

Of the patients assessed, 7 (43.8%) were diagnosed with mCRC and 9 (56.3%) with HNC. All patients treated with cetuximab for mCRC had wild type RAS status, according to the hospital's protocol.

Table 1 shows the baseline characteristics of the cetuximab patient population. In total, 9 of the patients (56.3%) on cetuximab treatment had epidermoid histology and 7 (43.8%) had adenocarcinoma. At study inclusion, all patients (100%) were in stage IV, although 4 (25%) had no metastases (HNC patients), and 7 patients (43.8%) were receiving first-line treatment for metastatic disease (median; 1 prior line; maximum, 3).

A total of 30 samples were analysed (minimum: 1 concentration per patient; maximum, 4; median 1.9). We observed marked inter- and intraindividual variability (standard deviation: 32.4 and 16.9 mg/L, respectively). The median  $C_{\text{trough, SS}}$  was 26.86 mg/L (P25-P75 = 16.29-69.72); Table 2 shows its breakdown by clinical benefit.

To address the main objective, the 30 samples from 16 mCRC and HNC patients were analysed together: 14 samples from 7 mCRC patients and 16 samples from 9 HNC patients. Clinical benefit was observed in 12/14 (86%) measurements in 6 mCRC patients and in 10/16 (63%) measurements in 7 HNC patients. The GEE model suggested a positive association between  $C_{\text{trough, SS}}$  and clinical benefit (OR 1.24; 95%CI: 0.95-1.63; *P* = 0.113), although it did not reach statistical significance due to low power. To achieve 80% power, 56 patients would be needed. Figure 1 shows the probability of clinical benefit predicted by the model at  $C_{\text{trough, SS}}$  intervals of 20 mg/L cetuximab.

The median follow-up of the 7 mCRC patients on cetuximab treatment was 27 months (95%CI: 11.13-not estimable) and the median OS was not reached. Cox regression showed no association between median  $C_{\text{trough, SS}}$  (HR 0.99; 95%CI: 0.95-1.05; *P* = 0.938) or last  $C_{\text{trough, SS}}$  (HR 1.04; 95%CI: 0.98-1.11; *P* = 0.212) and OS. Median PFS was 16 months (95%CI: 4.03-not estimable). In this case, there was also no association between the median  $C_{\text{trough, SS}}$  (HR 0.96; 95%CI: 0.92-1.01; *P* = 0.152) and PFS, nor with the final  $C_{\text{trough, SS}}$  (HR 1.02; 95%CI: 0.97-1.07; *P* = 0.442).

In the case of the 7 HNC patients on cetuximab treatment, the median follow-up was 19 months (95%CI: 17-not estimable) and the median OS was also not reached. Cox regression showed no association between median  $C_{\text{trough, SS}}$  (HR 0.99; 95%CI: 0.91-1.07; *P* = 0.746) or the final  $C_{\text{trough, SS}}$  (HR 1.04; 95%CI: 0.94-1.16; *P* = 0.416) and the OS. Median PFS was 12 months (95%CI: 4.4-not estimable) and there was also no association between median  $C_{\text{trough, SS}}$  (HR 1.02; 95%CI: 0.95-1.08; *P* = 0.616) and PFS, nor with final  $C_{\text{trough, SS}}$  (HR 1.12; 95%CI: 0.99-1.27; *P* = 0.063).

The ROC curve analysis (*n* = 30) had acceptable discrimination power (AUC-ROC 0.710; 95%CI: 0.49-0.93). The estimated cutoff point, with the highest sensitivity (73%) and specificity (63%), was 19.12 mg/L (Figure 2).

**Table 1.** Baseline characteristics of the patient population on cetuximab

| Characteristic   | Median   | Interquartile range |
|--|----------|---------------------|
| <b>Continuous variables</b>  |          |                     |
| Age at inclusion, years  | 73       | 69-75               |
| Weight, kg   | 65       | 58-71               |
| Height, cm   | 160      | 158-163             |
| Body surface area, cm <sup>2</sup>                                       | 1.69     | 1.59-1.74           |
| <b>Categorical variables</b>   |          |                     |
|  | <b>n</b> | <b>%</b>            |
| <b>Sex</b>   |          |                     |
| Men  | 12       | 75                  |
| Women  | 4        | 25                  |
| <b>Primary tumour location</b>   |          |                     |
| Colorectal   | 7        | 43.8                |
| Colon  | 4        |                     |
| Rectum   | 3        |                     |
| Head and neck  | 9        | 56.3                |
| Oropharynx   | 4        |                     |
| Larynx   | 4        |                     |
| Pharynx  | 1        |                     |
| <b>ECOG PS at diagnosis</b>  |          |                     |
| 0  | 4        | 25.0                |
| ≥ 1  | 12       | 75.0                |
| <b>Pulmonary metastases at inclusion</b>                                 |          |                     |
|  | 7        | 43.8                |
| <b>Peritoneal metastases at inclusion</b>                                |          |                     |
|  | 6        | 37.5                |
| <b>Hepatic metastases at inclusion</b>                                   |          |                     |
|  | 4        | 25.0                |
| <b>Other location of metastases at inclusion</b>                         |          |                     |
|  | 5        | 31.3                |
| <b>No. of organs affected</b>  |          |                     |
| 0-1  | 10       | 62.5                |
| ≥ 2  | 6        | 37.5                |
| <b>No. of metastases</b>   |          |                     |
| 0  | 4        | 25.0                |
| 1-5  | 7        | 43.8                |
| 6-10   | 4        | 25.0                |
| > 10   | 1        | 6.3                 |
| <b>Comorbidities</b>   |          |                     |
| 0  | 5        | 31.3                |
| ≥ 1  | 11       | 68.8                |
| <b>Chemotherapy schedule at inclusion (standard regimen + cetuximab)</b> |          |                     |
| <b>Weekly cetuximab monotherapy</b>                                      |          |                     |
| FOLFIRI  | 3        | 18.8                |
| Irinotecan   | 1        | 6.3                 |
| Paclitaxel + carboplatin, weekly   | 7        | 43.8                |
| mFOLFOX6   | 1        | 6.3                 |
| XELOX  | 1        | 6.3                 |
| <b>Cetuximab, posology</b>   |          |                     |
| 250 mg/m <sup>2</sup> /wk  | 11       | 68.8                |
| 500 mg/m <sup>2</sup> /2 wks   | 5        | 31.3                |

ECOG PS: Eastern Cooperative Oncology Group Scale of Performance Status; FOLFIRI: (Folínico/Fluorouracilo/Irinotecán); mFOLFOX6: (Folínico/Fluorouracilo/oxaliplatin); XELOX: (Oxaliplatin/capecitabina).

**Table 2.** Median  $C_{\text{trough, SS}}$  by clinical benefit subgroups

| Clinical benefit  | No. of samples | Median $C_{\text{trough, SS}}$ (mg/L) |
|-------------------|----------------|---------------------------------------|
| Stable disease    | 3              | 25.00                                 |
| Partial response  | 16             | 43.74                                 |
| Complete response | 3              | 66.54                                 |


$C_{\text{trough, SS}}$ : trough concentration at steady state.

## Discussion


Our study failed to prove an association between cetuximab  $C_{\text{trough, SS}}$  and clinical benefit in patients with mCRC or HNC. The GEE model found an association between each additional 10 mg/L of cetuximab and a 24% probability of response, although without reaching statistical significance due to low statistical power. To achieve 80% power, 56 patients would be required. Neither was an association found between the median  $C_{\text{trough, SS}}$  and OS or PFS, or with the final  $C_{\text{trough, SS}}$  in both pathologies. Moreover, in the HNC patient group, the association between cetuximab  $C_{\text{trough, SS}}$  and clinical benefit was inverted, because since there was a trend toward a higher risk of progression with higher final concentrations, which bordered on statistical significance ( $P = 0.063$ ).

To our knowledge, only Becher *et al.*<sup>20</sup> have previously assessed the association between cetuximab  $C_{\text{trough, SS}}$  and disease control. They studied the association between  $C_{\text{trough, SS}}$  and treatment efficacy 3 months after cetuximab initiation in 25 patients with native KRAS and NRAS HNC under clinical practice conditions. They found statistically significant differences between the  $C_{\text{trough, SS}}$  of patients with clinical benefit and the  $C_{\text{trough, SS}}$  of non-responding patients ( $49.0 \pm 16.3$  mg/L vs  $25.8 \pm 17$  mg/L;  $P < 0.01$ , *t*-test), according to RECIST 1.0 criteria. On the other hand, Pointreau *et al.*<sup>15</sup> conducted a retrospective study in 34 patients with HNC treated with monotherapy or with chemotherapy and/or radiotherapy, finding a statistically significant association between global clearance and overall survival. Both PFS (14.1 months vs 11.6 months;  $P = 0.037$ ) and OS (16.56 months vs 6.34 months;  $P = 0.007$ ) were higher in patients with cetuximab global clearance values lower than a median of 0.747 L/d. These results suggest that greater exposure to cetuximab may increase survival times (this premise was not tested in their study). In a PK/PD study, Le Louedec *et al.*<sup>16</sup> obtained data from 16 patients with  $C_{\text{trough}}$  and tumour response. This study was part of a prospective, nonrandomized, multicentre, open-label, clinical trial in patients with metastatic or recurrent HNC who were treated with platinum, fluorouracil, and cetuximab as first-line therapy. Patients were classified into two groups according to their tumour response as measured using RECIST 1.1 criteria: response to treatment and progression. Patients with response had a higher  $C_{\text{trough}}$  than patients with

**Figure 1.** Probability of clinical benefit predicted by the model, at cetuximab  $C_{\text{trough, SS}}$  intervals of 20 mg/L. Vertical lines represent 95% confidence intervals (95%CI).



**Figure 2.** ROC curve of  $C_{\text{trough, SS}}$  of cetuximab.



progression, both at day 7 (42.6 vs 18.8 mg/L;  $P = 0.03$ ) and at day 21 (47.4 vs 19.0 mg/L;  $P = 0.04$ ). They also found an association between  $C_{\text{trough}}$  and performance status (PS) and between PFS and PS. By stratifying patients according to their  $C_{\text{trough}}$  on day 7 with the median as the cutoff value (29 mg/L), median PFS was 194 days in patients with a higher  $C_{\text{trough}}$  vs 106 days in patients with a lower  $C_{\text{trough}}$  ( $P = 0.0503$ ;  $n = 23$ ). In this study, because low cetuximab concentrations were associated with worse PS, the authors could not conclude that low exposure, rather than patients' PS, was responsible for shorter PFS. In a study on patients with native KRAS mCRC, Azzopardi *et al.*<sup>14</sup> found an association between cetuximab global clearance and  $C_{\text{trough}}$  at day 14 and PFS ( $P = 0.013$  and  $P = 0.03$ , respectively); Jiang *et al.*<sup>18</sup> suggested that standard doses of cetuximab are not optimal for all patients, because patients with lower clearance have better PFS and OS; and the EVEREST study<sup>9</sup> found that native KRAS patients who received maintenance weekly doses of more than 250 mg/m<sup>2</sup> had higher concentrations, higher overall response rates, and higher PFS, although the differences did not reach statistical significance.

Regarding target  $C_{\text{trough, SS}}$ , Robert *et al.*<sup>6</sup> suggested that the biologically optimal dose of cetuximab is the lowest dose needed to maintain continuous zero-order clearance. This saturation has been shown to be achieved with maintenance doses of 250 mg/m<sup>2</sup>.<sup>5</sup> However, in simulations of plasma concentrations in patients with different body surface areas, larger patients reached higher steady-state concentrations and therefore the risk of underexposure in smaller patients could not be excluded<sup>30</sup>. On the other hand, Becher *et al.*<sup>20</sup> noted that  $C_{\text{trough}}$  was more relevant than  $C_{\text{max}}$  in relation to efficacy, which would again point to the need for constant inhibition of the EGFR targets with sustained cetuximab levels until the next administration. Given this background, it would seem to be essential to have a predictive biomarker of efficacy. In our study, we looked for a threshold  $C_{\text{trough, SS}}$  associated with clinical benefit as a biomarker, but the 95%CI of the AUC-ROC included values of less than 0.5, which may have been due to the small sample size, among other factors. We did not study the degree of EGFR expression, which could vary over time and influence clearance. Becher *et al.*<sup>20</sup> found an association between a  $C_{\text{trough, SS}}$  of 33.8 mg/L and clinical benefit (ROC curve: 78% specificity and 87% sensitivity; Fisher's exact test: OR 18.6; 95%CI: 1.9-327.8;  $P = 0.003$ ), measured by liquid chromatography-tandem mass spectrometry.

In our study, the failure to find a statistically significant association between exposure and response may be due to the limitations of patient recruitment, being conducted in a single-centre, and the small sample



size. As with any study conducted during clinical practice, failure may also be due to high inter- and intra-individual variability in concentrations, the inclusion of 2 patients with oesophageal cancer, low correlation between response rate and survival, or differences in dosing regimens, chemotherapy schedules, and treatment lines. Furthermore, although it may seem reasonable to identify target concentrations of oncological mAb by comparing exposure and disease control, this approach may not be the best option<sup>11</sup>. All these aspects may have contributed to a failure to adequately assess the effect.

In conclusion, despite the low statistical power of the analysis and, therefore, the lack of statistical significance, we found that a cutoff point for cetuximab of more than 19 mg/L could be associated with good response to treatment. This result could help in the design of future studies with a larger sample size.

Progress in monitoring the mAbs used in oncology should come from prospective multicentre trials that can establish the exposure-response relationship, determine an objective value of efficacy per indication, and demonstrate benefit after increasing the dose in patients with low concentrations. This approach would make it possible to optimize treatment efficiency.

## Funding

This work was supported by the Fundación Universidad Alfonso X el Sabio and the Santander Group through the VIII Convocatoria Proyectos de Investigación (project number: 1.010.708).

## Bibliography

1. Red Española de Registros de Cáncer (REDECAN). Estimaciones de la incidencia del cáncer en España, 2021; Madrid, España: REDECAN; 2021.
2. Gómez-España MA, Gallego J, González-Flores E, Maurel J, Pérez D, Sastre J, *et al.* SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). *Clin Transl Oncol.* 2019;21(11):46-54. DOI: 10.1007/s12094-018-02002-w
3. Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica de Erbitux 5 mg/ml solución para perfusión [Internet]. Ministerio de Sanidad, Servicios Sociales e Igualdad. 2020 [accessed 10/17/2021]. Available at: [https://www.ema.europa.eu/en/documents/product-information/erbituxepar-product-information\\_es.pdf](https://www.ema.europa.eu/en/documents/product-information/erbituxepar-product-information_es.pdf)
4. Fracasso PM, Burris H, Arquette MA, Govidan R, Gao F, Wright LP, *et al.* A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: Pharmacokinetic and pharmacodynamic rationale for dosing. *Clin Cancer Res.* 2007;13(3):986-93. DOI: 10.1158/1078-0432.CCR-06-1542
5. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, *et al.* Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. *J Clin Oncol.* 2000;18(4):904-14. DOI: 10.1200/jco.2000.18.4.904
6. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, *et al.* Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. *J Clin Oncol.* 2001;19(13):3234-43. DOI: 10.1200/JCO.2001.19.13.3234
7. Mathijssen RHJ, De Jong FA, Loos WJ, Van der Bol JM, Verweij J, Sparreboom A. Flat-Fixed Dosing Versus Body Surface Area Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference? *Oncologist.* 2007;12(8):913-23. DOI: 10.1634/theoncologist.12-8-913
8. Nolting A, Fox FE, Kovar A. Clinical drug development of cetuximab, a monoclonal antibody. En: Meibohm B, ed. *Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development.* Weinheim, Germany: Wiley-VCH; 2006:353-70.
9. Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Levêque D, *et al.* Review of therapeutic drug monitoring of anticancer drugs part two - Targeted therapies. *Eur J Cancer.* 2014;50(12):2020-36. DOI: 10.1016/j.ejca.2014.04.015
10. Wang DD, Shuzhong Z, Hong Z, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. *J Clin Pharmacol.* 2009;49(9):1012-24. DOI: 10.1177/0091270009337512
11. Oude Munnink TH, Henstra MJ, Segerink IJ, Movig KLL, Brummelhuis-Visser P. Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF- $\alpha$  experience to oncology. *Clin Pharmacol Ther.* 2016;99(4):419-31. DOI: 10.1002/cpt.211
12. Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H. Evidence

## Acknowledgments

We would like to thank all the staff of the Hospital Universitario Severo Ochoa who, in their various ways, contributed to the completion of this project.

## Conflict of interest

No conflicts of interests.

## Presentation at congresses

The work has been previously presented at the 66th SEFH Congress in the category of I+D Projects.

## Contribution to the scientific literature

Since 2004, cetuximab has been used in clinical practice to treat various neoplasms, but there is a lack of a biomarker to predict its efficacy and of relevant information on its exposure-response relationship. This study adds to the evidence on the relationship between cetuximab concentrations and its clinical efficacy, and addresses the issue of a target concentration.

- for therapeutic drug monitoring of targeted anticancer therapies. *J Clin Oncol.* 2012;30(32):4017-25. DOI: 10.1200/JCO.2012.43.5362
13. Ferrer F, Fanciullino R, Milano G, Ciccolini J. Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations. *Clin Pharmacol Ther.* 2020;108(3):458-70. DOI: 10.1002/cpt.1954
14. Azzopardi N, Lecomte T, Ternant D, Boisdrion-Celle M, Piller F, Morel A, *et al.* Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. *Clin Cancer Res.* 2011;17(19):6329-37. DOI: 10.1158/1078-0432.CCR-11-1081
15. Pointreau Y, Azzopardi N, Ternant D, Calais G, Paintaud G. Cetuximab Pharmacokinetics Influences Overall Survival in Patients with Head and Neck Cancer. *Ther Drug Monit.* 2016;38(5):567-72. DOI: 10.1097/FTD.0000000000000321
16. Le Louedec F, Alix-Panabières C, Lafont T, Allal BC, Garrel R, Digue L, *et al.* Cetuximab pharmacokinetic/pharmacodynamic relationships in advanced head and neck carcinoma patients. *Br J Clin Pharmacol.* 2019;85(6):1357-66. DOI: 10.1111/bcp.13907
17. Dirks NL, Nolting A, Kovar A, Meibohm B. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. *J Clin Pharmacol.* 2008;48(3):267-78. DOI: 10.1177/0091270007313393
18. Jiang DM, Sim HW, Siu LL, Shapiro JD, Liu G, Jay T, *et al.* Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC). *J Clin Oncol.* 2017;35(4\_suppl):699-699. DOI: 10.1200/jco.2017.35.4\_suppl.699
19. Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, *et al.* Inpatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: The randomized EVEREST study. *J Clin Oncol.* 2012;30(23):2861-68. DOI: 10.1200/JCO.2011.40.9243
20. Becher F, Ciccolini J, Imbs DC, Marin C, Fournel CI, Dupuis C, *et al.* A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients OPEN. *Sci Rep.* 2017;7(2714):1-11. DOI: 10.1038/s41598-017-02821-x
21. Strik AS, Wang YMC, Ruff LE, Yashar W, Messmer BT, Mould DR. Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm? *AAPS J.* 2018;20(99):1-10. DOI: 10.1208/s12248-018-0257-y
22. Vande Castele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. *Gastroenterology.* 2017;153:835-57. DOI: 10.1053/j.gastro.2017.07.031
23. Menting SP, Coussens E, Pouw MF, Van den Reek J, Temmerman L, Boonen H, *et al.* Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis a step toward personalized treatment. *JAMA Dermatol.* 2015;151(6):616-22. DOI: 10.1001/jamadermatol.2014.5479

24. Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, *et al.* Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. *Ann Rheum Dis.* 2015;74(3):1-9. DOI: 10.1136/annrheumdis-2013-203893
25. Pouw MF, Kriekkaert CL, Nurmohamed MT, Van der Kleij D, Aarden L, Rispens T, *et al.* Key findings towards optimising adalimumab treatment: The concentration-effect curve. *Ann Rheum Dis.* 2015;74(3):513-8. DOI: 10.1136/annrheumdis-2013-204172
26. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compennolle G, Van Steen K, *et al.* Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease. *Gastroenterology.* 2015;148:1320-9. DOI: 10.1053/j.gastro.2015.02.031
27. Bardin C, Veal G, Paci A, Chatelut E, Astier A, Levêque D, *et al.* Therapeutic drug monitoring in cancer-Are we missing a trick? *Eur J Cancer.* 2014;50:2005-09. DOI: 10.1016/j.ejca.2014.04.013
28. Hanley J, Negassa A, Edwardes M, Forrester J. Statistical Analysis of Correlated Data Using Generalized Estimating Equations: An Orientation. *Am J Epidemiol.* 2003;157(4):364-75. DOI: 10.1093/aje/kwf215
29. Clark TG, Bradburn MJ, Love SB, Altman DG. Survival Analysis Part I: Basic concepts and first analyses. *Br J Cancer.* 2003;89(2):232-8. DOI: 10.1038/sj.bjc.6601118
30. Committee for Medicinal Products for Human Use. Erbitux EPAR-Scientific Discussion. Initial Marketing-Authorisation Documents [Internet]. European Medicine Agency. 2006 [accessed 10/17/2021]. Available at: [https://www.ema.europa.eu/en/documents/scientific-discussion/erbitux-epar-scientific-discussion\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-discussion/erbitux-epar-scientific-discussion_en.pdf)